Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
July 21, 2022 16:05 ET
|
Plus Therapeutics Inc.
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186RNL to support...
Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022
July 13, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
July 12, 2022 07:00 ET
|
Plus Therapeutics Inc.
Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and...
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
June 22, 2022 07:30 ET
|
Plus Therapeutics Inc.
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to...
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
June 16, 2022 07:30 ET
|
Plus Therapeutics Inc.
Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data Safety & Monitoring Board to consider further...
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
June 13, 2022 07:05 ET
|
Plus Therapeutics Inc.
Data validates continued high radiation absorbed of 186RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure Company will also present at...
Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference
May 18, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics to Present at the 2022 Q2 Investor Summit
April 26, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
April 21, 2022 16:05 ET
|
Plus Therapeutics Inc.
First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases Closed in-licensing transaction for novel targeted radioembolic...
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
April 19, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...